金活医药集团(01110)发布中期业绩 股东应占亏损541.2万元 同比盈转亏

Group 1 - The company reported a revenue of RMB 405 million for the six months ending June 30, 2025, representing a year-on-year decrease of 23% [1] - The company experienced a loss attributable to shareholders of RMB 5.412 million, marking a shift from profit to loss compared to the previous year [1] - The loss per share was recorded at 0.94 cents [1]